Searched for
DIABETES MANAGEMENT
Stock picks of the week: 5 stocks with consistent score improvement and upside potential of up to 26%On Thursday evening, US President Trump said he would “hit Iran hard tonight”. Then, as the world waited with bated breath, came the announ...
These mid-cap stocks with ‘Strong Buy’ & ‘Buy’ recos can rally over 27%, according to analystsWe are in a phase in the US-Israel-Iran war where statements are made, then retracted. And, in a matter of just 48 hours, they are made all...
These large- and mid-cap stocks can give more than 25% return in 1 year, according to analystsThere are market phases when one risk dominates. Then there are phases like this, when risks arrive from every direction and refuse to stan...
Hair loss due to soft drinks: Hair transplant surgeon explains whether drinking soda with meals can make you go baldCold drink causing hair loss: Daily cold drink habits might affect hair health. Doctors note a link between sugary beverages and conditions...
Hetero partners with Richter to develop, market Semaglutide injection globallyHyderabad's Hetero Labs partners with European giant Gedeon Richter. They will jointly develop and sell Semaglutide Injection, the generic ...
5 mid-cap stocks from different sectors with an upside potential of 13 to 24% in one year, according to analystsWhen mid-caps were rising, every concern on valuation was treated as unnecessary caution. Investors who advised patience were told they wer...
In 1889, a physician noticed a sweet urine clue and helped point medicine toward insulinIn a groundbreaking moment in 1889, two German scientists, Joseph von Mering and Oskar Minkowski, uncovered a crucial link between the panc...
Stock picks of the week: 6 stocks with consistent score improvement and upside potential of up to 29%At a time when there are so many headwinds for the markets, it is tough to imagine that things can get better. But sentiment is a fickle th...
These large- and mid-cap stocks may give more than 25% return in 1 year, according to analystsFor the last few earnings seasons, the message has been: “Show me growth, I have the money.” Stocks with better-than-expected earnings saw ...
Zydus Semaglutide approval: Delhi HC directs CDSCO to decide on patient safety concernsThe Delhi High Court has asked the Central Drugs Standard Control Organisation to review a petition challenging Zydus Lifesciences' approva...
Alkem Labs shares in focus as Goldman, Morgan Stanley, others purchase stake in Rs 930-crore block dealShares of Alkem Laboratories will be in focus after block deals worth around Rs 930 crore saw 17.88 lakh shares traded at Rs 5,200 apiece o...
Should you buy OPD cover in health insurance? Over 40% of healthcare costs are paid out-of-pocket in IndiaOPD cover in health insurance addresses out-of-pocket expenses for doctor visits, diagnostics, and medicines without hospitalization. While...
Alkem rolls out single-shot semaglutide syringes at Rs 350 for diabetes, weight lossAlkem Laboratories has launched semaglutide in single-shot pre-filled syringes in India. This makes treatment more accessible and affordabl...
Good news for diabetes & BP patients: Govt cuts prices of these 30 medicines, relief may reach pharmacies soonThe National Pharmaceutical Pricing Authority (NPPA) has fixed retail prices for 30 essential drug formulations, including those for diabet...
Homeopathy doctor shares simple tips to reduce facial and belly fat; says your future self will thank youHealth experts warn that facial puffiness and belly fat, particularly visceral fat, are serious health indicators. Dr. Sayajirao Gaikwad em...
Cipla is aiming for 40-50 global product filings in three years, says MD Achin GuptaCipla is charting its next growth phase with a strong focus on innovation, complex generics, and biosimilars. The company plans significant...
Innovation, biosimilars, complex generics to drive Cipla's growth: Achin Gupta, MD & Group CEOAs Cipla approaches its centenary, the company is redefining its strategy by prioritizing innovation to amplify revenues. With ambitions to...